Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) [Phase 3]
A Phase III randomized trial evaluating neoadjuvant chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negativ…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. [Phase 2]
Phase 2 clinical trial evaluating whether infrared laser spectroscopy analysis of liquid biopsies can predict the efficacy of palbociclib in…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: TH1902 in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for TH1902 in patients with advanced solid tumors. The study is currently active/not recruiting and …
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer [NA]
This clinical trial is evaluating sirolimus albumin-bound in combination with palbociclib and fulvestrant for advanced HR-positive, HER2-neg…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
PALMARES-2 is a multicenter Italian study evaluating the ability to predict outcomes for patients with advanced HR-positive, HER2-negative b…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating chidamide in combination with angiogenesis inhibitors and fulvestrant for advanced HR-positive, HER2-…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
A recruiting clinical trial evaluating anlotinib-based combination therapy for hormone receptor-positive metastatic breast cancer, sponsored…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial [Phase 2]
Phase II neoadjuvant trial assessing pyrotinib in combination with chemotherapy for HER2-low-expressing, hormone receptor-positive breast ca…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors [Phase 1]
Phase 1 study evaluating XL092 as a single-agent and combination therapy for solid tumors, including renal cell carcinoma, hormone receptor-…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Phase 2]
A Phase 2 clinical trial assessing SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
This clinical trial update describes a retrospective observational study evaluating the safety and toxicity management of abemaciclib in com…
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
This document notes that a clinical trial evaluating treatment for ESR1-mutated HR+/HER2- advanced breast cancer in Chinese patients is curr…
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative [Phase 3]
Phase III trial status update for SHR6390 in combination with placebo and endocrine therapy as adjuvant treatment for hormone receptor-posit…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study [Phase 2]
A multicenter, single-arm Phase II trial assessing dalpiciclib in combination with toremifene for first-line advanced hormone receptor-posit…
-
CLINICAL_TRIALS research · 2024-06-24Clinical Trial Update: To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating Adebrelimab in combination with chemotherapy after HIFU-based neoadjuvant therapy for hormone receptor-pos…
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
Real-world study from Portugal (REVEAL) reports on treatment patterns with cyclin-dependent kinase inhibitors in advanced breast cancer; the…
-
CLINICAL_TRIALS research · 2024-06-07Clinical Trial Update: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer [Phase 3]
This is a Phase 3 clinical trial update evaluating apatinib in combination with a CDK4/6 inhibitor as first-line therapy for HR+/HER2- breas…
-
CLINICAL_TRIALS research · 2018-04-09Clinical Trial Update: Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers [Phase 3]
Phase 3 trial update evaluating whether using circulating tumor cells to guide first-line treatment for metastatic, hormone-receptor-positiv…
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer [Phase 2]
This Phase 2 clinical trial compares capecitabine versus endocrine therapy as a maintenance regimen after second-line treatment in hormone r…
-
CLINICAL_TRIALS research · 2016-06-15Clinical Trial Update: Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer [Phase 3]
This document provides an update on a Phase 3 clinical trial evaluating a combination of fulvestrant, everolimus, and exemestane for metasta…